PLoS ONE 2010-01-01

Immunization with pre-erythrocytic antigen CelTOS from Plasmodium falciparum elicits cross-species protection against heterologous challenge with Plasmodium berghei.

Elke S Bergmann-Leitner, Ryan M Mease, Patricia De La Vega, Tatyana Savranskaya, Mark Polhemus, Christian Ockenhouse, Evelina Angov

Index: PLoS ONE 5(8) , e12294, (2010)

Full Text: HTML

Abstract

The Plasmodium protein Cell-traversal protein for ookinetes and sporozoites (CelTOS) plays an important role in cell traversal of host cells in both, mosquito and vertebrates, and is required for successful malaria infections. CelTOS is highly conserved among the Plasmodium species, suggesting an important functional role across all species. Therefore, targeting the immune response to this highly conserved protein and thus potentially interfering with its biological function may result in protection against infection even by heterologous species of Plasmodium.To test this hypothesis, we developed a recombinant codon-harmonized P. falciparum CelTOS protein that can be produced to high yields in the E. coli expression system. Inbred Balb/c and outbred CD-1 mice were immunized with various doses of the recombinant protein adjuvanted with Montanide ISA 720 and characterized using in vitro and in vivo analyses.Immunization with PfCelTOS resulted in potent humoral and cellular immune responses and most importantly induced sterile protection against a heterologous challenge with P. berghei sporozoites in a proportion of both inbred and outbred mice. The biological activity of CelTOS-specific antibodies against the malaria parasite is likely linked to the impairment of sporozoite motility and hepatocyte infectivity. The results underscore the potential of this antigen as a pre-erythrocytic vaccine candidate and demonstrate for the first time a malaria vaccine that is cross-protective between species.


Related Compounds

Related Articles:

Protection against an intranasal challenge by vaccines formulated with native and recombinant preparations of the Chlamydia trachomatis major outer membrane protein.

2009-08-06

[Vaccine 27(36) , 5020-5, (2009)]

Phase 1 safety and immunogenicity trial of the Plasmodium falciparum blood-stage malaria vaccine AMA1-C1/ISA 720 in Australian adults.

2010-03-02

[Vaccine 28(10) , 2236-42, (2010)]

Effects on immunogenicity by formulations of emulsion-based adjuvants for malaria vaccines.

2012-10-01

[Clin. Vaccine Immunol. 19(10) , 1633-40, (2012)]

Pichia pastoris-expressed dengue virus type 2 envelope domain III elicits virus-neutralizing antibodies.

2010-07-01

[J. Virol. Methods 167(1) , 10-6, (2010)]

CpG oligodeoxynucleotide and montanide ISA 206 adjuvant combination augments the immune responses of a recombinant FMDV vaccine in cattle.

2011-10-19

[Vaccine 29(45) , 7960-5, (2011)]

More Articles...